CHRISTIE BALLANTYNE to Platelet Aggregation Inhibitors
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Platelet Aggregation Inhibitors.
Connection Strength
2.121
-
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 01 03; 380(1):11-22.
Score: 0.533
-
Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7. Cardiovasc Drugs Ther. 2022 02; 36(1):93-102.
Score: 0.155
-
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. Circulation. 2021 01 05; 143(1):33-44.
Score: 0.153
-
Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. J Am Coll Cardiol. 2019 08 27; 74(8):1159-1161.
Score: 0.141
-
Effects of Icosapent Ethyl on Total?Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019 06 11; 73(22):2791-2802.
Score: 0.137
-
Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004817.
Score: 0.135
-
Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. J Am Heart Assoc. 2018 06 09; 7(12).
Score: 0.129
-
Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. J Womens Health (Larchmt). 2018 09; 27(9):1170-1176.
Score: 0.128
-
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016 10; 253:81-87.
Score: 0.114
-
Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. Am J Cardiol. 2016 Oct 15; 118(8):1144-1149.
Score: 0.114
-
Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg. 2011 Mar; 53(3):668-75.
Score: 0.077
-
Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. 2009 Jul; 102(1):179-80.
Score: 0.070
-
Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J. 2008 Nov; 156(5):1002.e1-1002.e7.
Score: 0.067
-
Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management. World J Surg. 2007 Apr; 31(4):695-704.
Score: 0.060
-
Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2021 07 01; 6(7):782-790.
Score: 0.040
-
Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. J Am Heart Assoc. 2017 Aug 03; 6(8).
Score: 0.031
-
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017 Mar; 40(3):138-148.
Score: 0.030
-
Hydrogen peroxide induces LFA-1-dependent neutrophil adherence to cardiac myocytes. Am J Physiol Heart Circ Physiol. 2000 Mar; 278(3):H835-42.
Score: 0.009